Viloxazine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 333056

CAS#: 35604-67-2 (HCl)

Description: Viloxazine, also known as SPN-812, is aselective norepinephrine reuptake inhibitor (NRI). Viloxazine was approved for medical use in the United States in April 2021 to treat attention deficit hyperactivity disorder (ADHD). Viloxazine, like imipramine, inhibited norepinephrine reuptake in the hearts of rats and mice; unlike imipramine, it did not block reuptake of norepinephrine in either the medullae or the hypothalami of rats. As for serotonin, while its reuptake inhibition was comparable to that of desipramine (i.e., very weak), viloxazine did potentiate serotonin-mediated brain functions in a manner similar to amitriptyline and imipramine, which are relatively potent inhibitors of serotonin reuptake. Unlike any of the other drugs tested, it did not exhibit any anticholinergic effects.


Chemical Structure

img
Viloxazine HCl
CAS# 35604-67-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 333056
Name: Viloxazine HCl
CAS#: 35604-67-2 (HCl)
Chemical Formula: C13H20ClNO3
Exact Mass: 0.00
Molecular Weight: 273.760
Elemental Analysis: C, 57.04; H, 7.36; Cl, 12.95; N, 5.12; O, 17.53

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 35604-67-2 (HCl)   46817-91-8 (free base)   21949-60-0 (acetate)  

Synonym: Viloxazine HCl; ICI 58,834; ICI-58,834; ICI58,834; ICI 58834; ICI-58834; ICI58834; SPN-812; SPN 812; SPN812;

IUPAC/Chemical Name: 2-((2-ethoxyphenoxy)methyl)morpholine hydrochloride

InChi Key: HJOCKFVCMLCPTP-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H

SMILES Code: CCOC1=CC=CC=C1OCC2OCCNC2.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 273.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nasser A, Kosheleff AR, Hull JT, Liranso T, Qin P, Busse GD, O'Neal W, Fava M, Faraone SV, Rubin J. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2021 Feb 17. doi: 10.1089/cap.2020.0148. Epub ahead of print. PMID: 33600233.

2: Faison SL, Fry N, Adewole T, Odebo O, Wang Z, Maletic V, Nasser A. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. J Clin Psychopharmacol. 2021 Mar-Apr 01;41(2):155-162. doi: 10.1097/JCP.0000000000001361. PMID: 33587403; PMCID: PMC7919699.

3: Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, O'Neal W, Rubin J, Nasser A. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Res. 2021 Feb;296:113664. doi: 10.1016/j.psychres.2020.113664. Epub 2021 Jan 5. PMID: 33418457.

4: Faison SL, Fry N, Adewole T, Odebo O, Schwabe S, Wang Z, Maletic V, Nasser A. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults. Clin Drug Investig. 2021 Feb;41(2):149-159. doi: 10.1007/s40261-020-00992-6. Epub 2020 Dec 23. PMID: 33368026; PMCID: PMC7886742.

5: Nasser A, Faison SL, Liranso T, Adewole T, Busse GD, Fava M, Kleiman RB, Schwabe S. Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults. J Clin Psychiatry. 2020 Oct 13;81(6):20m13395. doi: 10.4088/JCP.20m13395. PMID: 33049804.